103 unknown. 103 Phase 2, 21 Phase 1, 17 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 103 | Unknown 103 |
| Phase 1 | 21 | Unknown 21 |
| Phase 3 | 17 | Unknown 17 |
Follow Anemia: new trials by email Literature Review of Anemia trials Research Report on Anemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NAC for Hematopoietic Recovery in SAA N Acetyl L Cysteine - Aplastic Anemia | Phase 2 | Unknown | Peking University People's Hospital | 30 | 2024-07-25 | 2024-07-24 |
| PBM as Strategy to CABG Anemic Patients Bypass Graft (CABG) Erythropoietin, blood transfusion - Anemia, Coronary Disease | Phase 2 | Unknown | Federal University of São Paulo | 120 | 2024-06-01 | 2024-08-07 |
| Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors Sirolimus, Abatacept, MMF - Acute Leukemia, Myelodysplastic Syndromes | Phase 1 / Phase 2 | Unknown | Peking University People's Hospital | 6 | 2024-03-01 | 2024-03-21 |
| Efficacy and Safety of Avatrombopag vs. Avatrombopag Combined With rhTPO in the Treatment of SAA Avatrombopag, Avatrombopag +rhTPO - Anemia, Aplastic | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 60 | 2024-02-01 | 2024-02-12 |
| Lidocaine Intravenous in the Emergency Department For Sickle Cell Crisis Lidocaine Iv, Placebo - Sickle Cell Disease, Sickle Cell Crisis | Phase 2 | Unknown | Community Medical Center, Toms River, NJ | 100 | 2024-01-01 | 2023-08-29 |
| SMILES: Study of Montelukast in Sickle Cell Disease Montelukast, Oral Placebo - Anemia, Sickle Cell, Sleep-Disordered Breathing | Phase 2 / Phase 3 | Unknown | Great Ormond Street Hospital for Children NHS Foundation Trust | 200 | 2023-10-16 | 2023-11-01 |
| The Safety and Efficacy of Zanubrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia Zanubrutinib - Refractory/Relapsed Autoimmune Hemolytic Anemia | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 33 | 2023-09-01 | 2023-11-29 |
| Vitamin C to Quality of Life in Patients With Terminal Stage Pancreatic Cancer Ascorbate - Metastatic Pancreatic Cancer, Terminal Cancer | Phase 2 | Unknown | Fudan University | 20 | 2023-08-25 | 2024-06-06 |
| Efficacy and Safety of CsA+AVA in the Treatment of NSAA in the Elderly Ciclosporin, Avatrombopag - Aplastic Anemia | Phase 2 | Unknown | Peking Union Medical College Hospital | 30 | 2023-08-17 | 2023-12-08 |
| Cyclophosphamide Added to Standard Immunosuppressive Therapy With Herombopag as Front-line Therapy in Patients With Severe Aplastic Anemia Cyclophosphamide added to standard immunosuppressive therapy with herombopag - Severe Aplastic Anemia | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 43 | 2023-07-10 | 2024-09-25 |
| Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma Iron Isomaltoside 1000, Polysaccharide Iron Complex Pill, Intensity-modulated radiotherapy - Nasopharyngeal Carcinoma, Iron-deficiency | Phase 2 | Unknown | Sun Yat-sen University | 120 | 2023-05-05 | 2023-06-22 |
| Hemolysis Related Complications in SCD. A Phase II Study With Voxelotor Voxelotor 1500 mg oral per day (GBT440) for 48 weeks in patients with sickle-cell disease - Sickle Cell Disease | Phase 2 | Unknown | Assistance Publique - Hôpitaux de Paris | 30 | 2023-03-22 | 2023-09-21 |
| Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies umbilical cord derived mesenchymal stem cells - Hematologic Neoplasms, Neutropenia | Phase 1 / Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 181 | 2023-01-01 | 2023-01-05 |
| Avatrombopag Combined With IST as First-line Treatment for SAA avatrombopag - Severe Aplastic Anemia | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 53 | 2022-11-10 | 2023-02-09 |
| GVHD Prophylaxis by Addition of CD20 Monoclonal Antibody to the Conditioning Regimen in SAA With Treatment of Allo-HSCT CD20 monoclonal antibody, ATG - Aplastic Anemia | Phase 2 | Unknown | The First Affiliated Hospital of Soochow University | 100 | 2021-12-30 | 2022-08-24 |
| Treatment of (IDA) by (FPC) Delivered Via Infusion Pump in Patients Receiving Home Infusion Therapy Triferic AVNU, Placebo - Iron Deficiency Anemia | Phase 2 | Unknown | Rockwell Medical Technologies, Inc. | 75 | 2021-11-30 | 2021-11-08 |
| Testing SIROLIMUS in Beta-thalassemia Transfusion Dependent Patients (THALA-RAP) Sirolimus 0.5 mg - Beta-Thalassemia | Phase 2 | Unknown | Università degli Studi di Ferrara | 45 | 2021-04-13 | 2021-11-12 |
| Avatrombopag Usage in NSAA Avatrombopag 20 MG - Aplastic Anemia, Drug Effect | Phase 2 / Phase 3 | Unknown | Peking Union Medical College Hospital | 40 | 2021-02-01 | 2021-01-28 |
| The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia Ibrutinib - Refractory/Relapsed Autoimmune Hemolytic Anemia | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 18 | 2020-05-01 | 2024-09-25 |
| Gum Arabic as Anti-oxidant, Anti-inflammatory and Fetal Hemoglobin Inducing Agent in Sickle Cell Anemia Patients Acacia Senegal extract, Pectin - Sickle Cell Anemia in Children | Phase 2 / Phase 3 | Unknown | Al-Neelain University | 100 | 2020-02-15 | 2020-01-28 |
Showing 20 of 103. Sign in to see all of them.
Anemia, Aplastic (29) · Anemia, Sickle Cell (22) · beta-Thalassemia (13) · Myelodysplastic Syndromes (12) · Anemia, Iron-Deficiency (6) · Anemia, Refractory, with Excess of Blasts (6) · Neoplasms (5) · Thalassemia (5) · Anemia, Hemolytic (4) · Anemia, Refractory (4) · Bone Marrow Failure Disorders (4) · Anemia, Hemolytic, Autoimmune (3) · Hematologic Diseases (3) · Kidney Failure, Chronic (3)
Hemic and Lymphatic Diseases (103) · Hematologic Diseases (100) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (41) · Genetic Diseases, Inborn (39) · Anemia, Hemolytic (38) · Bone Marrow Diseases (38) · Anemia, Hemolytic, Congenital (36) · Hemoglobinopathies (34) · Bone Marrow Failure Disorders (28) · Pathological Conditions, Signs and Symptoms (22) · Pathologic Processes (16) · Cardiovascular Diseases (13) · Urogenital Diseases (13) · Female Urogenital Diseases and Pregnancy Complications (11)
Cyclosporine (6) · fludarabine (6) · Cyclophosphamide (5) · Sirolimus (4) · avatrombopag (4) · fludarabine phosphate (4) · Alemtuzumab (3) · Amifostine (3) · Busulfan (3) · Deferiprone (3) · Epoetin Alfa (3) · Hydroxyurea (3) · Levamisole (3) · Melphalan (3) · ferrous sulfate (3)
Institute of Hematology & Blood Diseases Hospital, China (8) · Ain Shams University (5) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (3) · Peking Union Medical College Hospital (3) · The Korean Society of Pediatric Hematology Oncology (3) · Groupe Francophone des Myelodysplasies (2) · Guangzhou General Hospital of Guangzhou Military Command (2) · New York Medical College (2) · Peking University People's Hospital (2) · Xiao-Lin Yin (2) · ALZA (1) · Al-Neelain University (1) · Albion (1) · Asan Medical Center (1) · Assistance Publique - Hôpitaux de Paris (1)
China (29) · United States (18) · South Korea (6) · United Kingdom (6) · Brazil (5) · Egypt (5) · France (3) · Italy (3) · Russia (3) · Austria (2) · Germany (2) · Iran (2) · Netherlands (2) · Pakistan (2) · Belgium (1)
Hyo Seop Ahn, M.D, Ph.D (2) · Liwei Fang, MD (2) · Yang Xiao, MD (2) · Yin X Lin, director (2) · A O Dosunmu, M.D. (1) · Aijun AJ Sun, MD (1) · Alessandro Aiuti, MD, PhD (1) · Anna Konstantinova, MD (1) · Ariel Koren, Professor (1) · Behjat Moayedi, Professor (1) · Beverley A de Valois, PhD (1) · Bruno Benites, MD (1) · Bruno Rotoli, MD (1)
PMID 20685256, PMID 29931453, PMID 18191732, PMID 20187965, PMID 22055111, PMID 22818551, PMID 22875626, PMID 23358617, PMID 23680589, PMID 23731760, PMID 23927461, PMID 24797180, PMID 25104129, PMID 25310303, PMID 25600572, PMID 25927273, PMID 26021713, PMID 26340878, PMID 28029503, PMID 28487769, PMID 29119631, PMID 29548623, PMID 29788942, PMID 29906796, PMID 30097463, PMID 32312326, PMID 32511251, PMID 34241801, PMID 34629091, PMID 37318085, PMID 37975597, PMID 38467031, PMID 38775255, PMID 38789134, PMID 38954844, PMID 41603130
2018 (2), 2014 (1), U54RR019397 (1)